Hereditary spherocytosis

Hereditary spherocytosis
Paulo Henrique Orlandi Mourao · CC BY-SA 3.0 · source
Name	Hereditary spherocytosis
Field	Hematology
Symptoms	Anemia, jaundice, splenomegaly, gallstones
Onset	Childhood to adulthood
Causes	Genetic defects in erythrocyte membrane proteins
Diagnosis	Blood smear, osmotic fragility, EMA binding test
Treatment	Splenectomy, folic acid, cholecystectomy

Hereditary spherocytosis is an inherited hemolytic anemia characterized by loss of erythrocyte membrane surface area, formation of spherocytes and shortened red cell survival. It presents across a spectrum from mild compensated hemolysis to severe transfusion‑dependent disease and often interacts with other medical, surgical, and public health contexts in pediatrics, internal medicine, and transfusion services.

Signs and symptoms

Patients commonly present with pallor, fatigue, and jaundice and may develop splenomegaly with abdominal pain. Neonatal presentation can include prolonged neonatal jaundice requiring evaluation by pediatricians from institutions such as Boston Children's Hospital or Great Ormond Street Hospital, while later childhood or adult presentations may be identified by internists at centers like Mayo Clinic or Johns Hopkins Hospital. Hemolytic exacerbations are often precipitated by infections seen in clinic cohorts at Centers for Disease Control and Prevention surveillance or by parvovirus B19 outbreaks investigated by World Health Organization. Complications such as pigment gallstones can necessitate consultation with surgeons at tertiary referral centers such as Cleveland Clinic or Mount Sinai Health System. Physical findings overlap with other hematologic disorders encountered at departments associated with Harvard Medical School and University of Oxford hematology units.

Genetics and pathophysiology

Pathogenic variants involve genes encoding erythrocyte membrane and cytoskeletal proteins, historically studied in laboratories affiliated with National Institutes of Health, Wellcome Trust Sanger Institute, and academic groups at University of Cambridge. Commonly implicated genes include ANK1, SPTA1, SPTB, SLC4A1, and EPB42, with inheritance patterns ranging from autosomal dominant to recessive; genetic counseling often involves teams at American College of Medical Genetics and Genomics clinics and genetic services at Stanford University. Molecular mechanisms were elucidated in work connected to investigators at Max Planck Society and Karolinska Institutet, demonstrating defects in ankyrin, spectrin, band 3, and protein 4.2 that reduce membrane stability and produce spheroidal erythrocytes prone to splenic sequestration, a concept explored in comparative physiology studies at institutions such as Smithsonian Institution and evolutionary analyses by researchers at University of California, Berkeley.

Diagnosis

Laboratory diagnosis integrates hematology workflows used across hospital systems like Kaiser Permanente and academic centers including Yale School of Medicine. Peripheral blood smear shows spherocytes; reticulocyte count and bilirubin measurement reflect hemolysis and are standard in laboratories operated by Quest Diagnostics and LabCorp. Specific tests include osmotic fragility testing developed in early clinical labs linked to Royal College of Physicians practice, eosin‑5′‑maleimide (EMA) binding flow cytometry performed in reference laboratories with protocols shared through networks such as European Hematology Association, and targeted genetic testing using panels validated by groups at American Society of Hematology. Differential diagnosis requires exclusion of autoimmune hemolytic anemia assessed by direct antiglobulin testing routinely used in transfusion services at American Red Cross and tertiary hospitals like University College London Hospitals.

Management and treatment

Initial management often includes folic acid supplementation and transfusion support following guidelines from organizations like National Institute for Health and Care Excellence and American Academy of Pediatrics. Splenectomy remains the definitive therapy for moderate to severe disease and is performed by surgical services at centers including Johns Hopkins Hospital and Mayo Clinic, with laparoscopic approaches popularized in practice by surgeons affiliated with Cleveland Clinic. Partial splenectomy and splenic embolization are alternatives studied at pediatric centers such as Boston Children's Hospital and Great Ormond Street Hospital. Cholecystectomy for symptomatic gallstones is coordinated with hepatobiliary teams at institutions like Massachusetts General Hospital. Emerging therapies and gene‑based approaches are investigated in trials supported by consortia including National Heart, Lung, and Blood Institute and biotech collaborations with groups in the European Union research networks.

Prognosis and complications

Prognosis ranges from near‑normal lifespan in mild cases to increased morbidity from complications such as severe anemia, aplastic crisis from parvovirus B19, pigment gallstones, and increased infection risk after splenectomy; these clinical courses are documented in long‑term cohort studies from centers like University of Toronto and King's College Hospital. Vaccination strategies against encapsulated organisms recommended by agencies such as Centers for Disease Control and Prevention and perioperative care protocols developed by Royal Australasian College of Surgeons mitigate post‑splenectomy risks. Obstetric management for pregnant patients with hemolytic disease involves multidisciplinary teams at maternal‑fetal medicine units in hospitals like Mount Sinai Health System and Brigham and Women's Hospital. Health economic analyses by groups at World Bank and outcome registries maintained by professional societies such as International Society of Hematology inform resource allocation and long‑term follow‑up.

Category:Inherited blood disorders